Imidazoquinolines use for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents whose mienbros target EGFR family

摘要

Use of the compound 2-methyl-2- [4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo [4,5-c] quinolin-1-yl) - phenyl] -propionitrile (Compound a) or a tautomer thereof, or a pharmaceutically acceptable salt, or a hidratoso solvates for the manufacture of a pharmaceutical preparation for the treatment of a disease dependent of EGFR, where the disease to be to be treated is - small cell lung carcinoma - head and neck cancer - colorectal carcinoma - breast cancer - brain malignancies including glioblastoma - prostate cancer - bladder cancer - renal cell carcinoma - pancreas cancer - cervical cancer - esophageal cancer - gastric cancer - ovarian cancer or any combination thereof.